Cencora, Inc. (COR)

NYSE · Health Care · Medical Distribution
By Alex · Tickerpine
$314.17
-19.70 (-5.90%)
Price — last 10 years monthly, dividend-adjusted · hover for detail
Market Cap
$59.95B
P/E (TTM)
24.8
Forward P/E
15.8
EPS (TTM)
$12.66
ROE
96.87%
Profit Margin
0.79%
Revenue Growth
5.10%
Dividend Yield
0.72%
Beta
0.57
52W High
$377.54
52W Low
$244.82
Analyst Target
$372.58

COR stock forecast: what analysts expect

Consensus rating
Buy
Avg. 12-month target
$372.58
Implied upside
+18.6%

Wall Street analysts covering Cencora, Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $372.58 — +18.6% versus the last price of $314.17. Targets reflect analyst opinion, not a guarantee.

What would an investment in COR be worth today?
Run COR through our free historical return calculator.
Calculate COR returns →

COR historical returns

PeriodTotal returnAnnualized (CAGR)$1,000 grew to
1 year +8.3% +8.4% $1,083
3 years +82.7% +22.2% $1,827
5 years +176% +22.5% $2,755
10 years +383% +17.1% $4,827
20 years +2,105% +16.7% $22,047
Since 1995 +17,657% +18.0% $177,567

Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in COR.

COR annual returns by year

2026 YTD -6.6%
2025 +51.5%
2024 +10.4%
2023 +25.3%
2022 +26.3%
2021 +44.1%
2020 +23.4%
2019 +23.5%
2018 -17.6%
2017 +19.5%

Congress trading in COR

3 members of Congress have disclosed trading COR — 1 purchase and 4 sales worth an estimated $64,500. Most recent disclosure: May 6, 2026.

Insider activity in COR

COR's own executives and directors have made 3 open-market purchases ($2.3M) and 0 sales ($0) in the last 90 days, per SEC Form 4 filings. Most recent: Jun 22, 2026.

Jun 22, 2026Tyler Lauren M Director Buy $148,626
Jun 18, 2026Durcan Dermot Mark Director Buy $1.1M
May 28, 2026Durcan Dermot Mark Director Buy $1.1M

About Cencora, Inc.

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Company website ↗

COR Key Statistics

Previous Close$333.87P/E Ratio24.8
Market Cap$59.95BPEG Ratio0.69
Revenue (TTM)$332.77BROE96.87%
Gross Margin3.96%ROA3.56%
Debt / Equity446.5Employees47,000

COR in plain English

COR stock: frequently asked questions

What is Cencora, Inc.'s stock price today?

Cencora, Inc. (COR) last traded at $314.17 on the NYSE. Over the past 52 weeks the stock has traded between $244.82 and $377.54.

Is COR stock a buy or a sell?

Wall Street analysts' consensus rating on COR is "Buy", with an average 12-month price target of $372.58 — about +18.6% versus the current price of $314.17. Analyst targets are opinions, not guarantees; always do your own research.

How much would $1,000 invested in COR 10 years ago be worth today?

A $1,000 investment in Cencora, Inc. made 10 years ago would be worth about $4,827 today (dividends reinvested) — a total return of 383%, or 17.1% per year.

Does COR pay a dividend?

Yes. Cencora, Inc. currently pays a dividend yielding about 0.72% per year at today's share price.

What is COR's P/E ratio?

COR trades at a trailing price-to-earnings ratio of 24.8, and 15.8 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.

Do members of Congress trade COR stock?

Yes — 3 members of Congress have disclosed trades in COR under the STOCK Act, totaling 1 purchases and 4 sales worth an estimated $64,500.

What is Cencora, Inc.'s ticker symbol?

Cencora, Inc. trades under the ticker symbol COR on the NYSE.

Compare COR with peers

COR vs LLYEli Lilly and Company $1,220.28 COR vs JNJJohnson & Johnson $260.86 COR vs ABBVAbbVie Inc. $248.76 COR vs UNHUnitedHealth Group Incorporated $405.59 COR vs MRKMerck & Company, Inc. $132.92

Data last refreshed from public sources. Figures may be delayed. Not investment advice.